Nasus Pharma Ltd has announced the appointment of Nir Sassi as its new Chief Financial Officer (CFO), effective November 11, 2026. This change in leadership is crucial as the company gears up for significant clinical developments, including the initiation of its pivotal NS002 study.

Nasus Pharma Ltd, a clinical-stage pharmaceutical company, operates under the SIC classification of Pharmaceutical Preparations (SIC 2834). The company is listed on the NYSE under the ticker NSRX. Recent filings indicate that Nasus is focused on developing innovative intranasal products, aiming to enhance patient treatment options.

The recent filing reveals that Mr. Sassi brings nearly 25 years of experience in public company finance and biopharmaceutical operations. He has previously served as CFO for Indaptus Therapeutics, Inc. and Intec Pharma Ltd. His educational background includes a bachelor’s degree in economics and accounting from Ben-Gurion University of the Negev, and he is a certified public accountant in Israel.

Udi Gilboa, Chairman of the Board of Directors, expressed confidence in Sassi's ability to lead the financial strategies of Nasus Pharma, stating, “Nir brings a wealth of financial leadership experience, a strong track record in the capital markets, and a deep understanding of the biopharmaceutical industry.”

Brendan O’Grady, CEO of Nasus Pharma, highlighted the importance of Sassi’s appointment as the company prepares to advance its NS002 product towards a pivotal clinical Phase 3 study, expected to commence in the fourth quarter of 2026. The study aims to provide a new intranasal alternative for patients experiencing severe allergic reactions.

As the company moves forward, Sassi's expertise in financial management is anticipated to play a critical role in supporting Nasus Pharma's growth and operational strategies. The filing does not specify what happens next, but the leadership transition is expected to enhance the company’s financial and operational capabilities.